Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717)

🧪 Interventions in This Study

• RMC-6291 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (64 Sites)

Showing the first 25 of 64 sites.

• Highlands Oncology Group — Springdale, Arkansas
• UC Irvine Cancer Center — Orange, California
• UC Davis Cancer Center — Sacramento, California
• UCSF — San Francisco, California
• University of Miami School of Medicine Sylvester Comprehensive Cancer Center — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• American Oncology Partners of Maryland — Bethesda, Maryland
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• MSK Cancer Center — New York, New York
• Columbia University Irving Medical Center — New York, New York
• Tennessee Oncology — Nashville, Tennessee
• Next Oncology — San Antonio, Texas
• START — San Antonio, Texas
• Next Oncology Virginia — Fairfax, Virginia
• Southside Cancer Care Centre — Sydney, New South Wales
• Peninsula & South Eastern Haematology and Oncology Group — Frankston, Victoria
• Austin Health, Olivia Newton-John Cancer Research & Wellness Centre — Heidelberg, Victoria
• South West Health Care — Warrnambool, Victoria
• NH Hospital a.s. — Hořovice,
• Klinika onkologie a radioterapie, Fakultni Nemocnice Hradec Kralove — Hradec Králové,
• Onkologicka klinika, Fakultni Nemocnice Olomouc — Olomouc,
• ICO — Angers,
• CHU Bordeaux Hospital Saint-Andre — Bordeaux,
• Centre Jean Perrin — Clermont-Ferrand,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Non-Small Cell Lung Cancer (NSCLC)

• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
• HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
• PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
• Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama

Explore by condition: All Non-Small Cell Lung Cancer (NSCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.